Galapagos NV (FRA:GXEA)

Germany flag Germany · Delayed Price · Currency is EUR
27.20
+0.40 (1.49%)
At close: Dec 4, 2025
4.62%
Market Cap 1.78B
Revenue (ttm) 286.92M
Net Income (ttm) -435.96M
Shares Out n/a
EPS (ttm) -6.62
PE Ratio n/a
Forward PE 8.54
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 17
Open 27.20
Previous Close 26.80
Day's Range 27.20 - 27.20
52-Week Range 19.90 - 31.40
Beta n/a
RSI 52.40
Earnings Date Feb 23, 2026

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 704
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol GXEA
Full Company Profile

Financial Performance

In 2024, Galapagos NV's revenue was 275.65 million, an increase of 14.99% compared to the previous year's 239.72 million. Earnings were 74.08 million, a decrease of -65.01%.

Financial Statements

News

There is no news available yet.